Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but These are unusual With this malignancy as compared to other lymphoid neoplasms. CHD2 See "Targeted therapies in CLL: mechanisms of resistance and strategies for management" on page 471. Duvelisib was the 2nd PI3K inhibitor authorized through https://emmaw763qxe0.wssblogs.com/profile